# A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

> **NCT05673993** · PHASE3 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 381 (actual)

## Conditions studied

- Primary Sjogren's Syndrome

## Interventions

- **BIOLOGICAL:** Telitacicept 80 mg
- **BIOLOGICAL:** Telitacicept 160 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05673993
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-06
- **Primary completion:** 2024-10-29
- **Final completion:** 2025-05-06
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673993, "A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05673993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*